Low Pancreatitis Rate Found for Youth on GLP-1 Drugs

A new study reveals that acute pancreatitis risk among young patients on GLP-1 receptor agonists is very low.

Updated on Oct. 7, 2026 in Diabetes

Bold vector editorial illustration of a stylized protein structure in shades of teal and sage, representing metabolic health research. — A study of over 33,000 young patients treated with GLP-1 receptor agonists found a very low incidence of acute pancreatitis over one year. AI Illustration. Upload story photo >

Live Poll

Do you trust the safety of weight-loss drugs for children and adolescents?

A study of over 33,000 patients aged 12 to 21 has identified a low incidence of acute pancreatitis among those treated with GLP-1 receptor agonists. The research found that only 0.243 percent of these young patients developed the condition over a period of at least one year.

Why it matters

Understanding the potential side effects of GLP-1 medications in younger demographics is critical as prescriptions for these drugs continue to rise. This data helps clarify safety profiles for clinical decision-making regarding long-term metabolic health in adolescents.

Researchers identified an incidence rate of 0.243 percent for acute pancreatitis within a study cohort of 33,765 patients. Semaglutide served as the most frequently prescribed agent, accounting for 63 percent of the group.

The players

American Academy of Pediatrics

This is an organization of pediatricians dedicated to the optimal physical, mental, and social health and well-being of infants, children, adolescents, and young adults.

The details

Using the TriNetX research network, investigators identified patients through validated ICD-10 codes while excluding alcohol-related cases. The study cohort consisted of 62.5 percent female participants, providing a broad look at youth undergoing treatment for at least one year.

October 7, 2026: The study was presented at the American Academy of Pediatrics meeting.

Health Landscape

This study utilizes the TriNetX research network to aggregate large-scale, real-world evidence for evaluating medication safety in pediatric populations. The research provides a significant milestone in documenting the safety of GLP-1 agonists beyond clinical trials.

This research may reassure families and clinicians about the pancreatic safety profile of common weight management medications in young patients. It highlights the importance of continued monitoring as providers balance the benefits of treatment against potential adverse events.

The takeaway

While the incidence rate of acute pancreatitis in this youth population was low, researchers maintain that ongoing surveillance remains a necessity. Prospective studies are encouraged to further define the long-term safety of these treatments for young patients.